The novel ADAMTS13-p.D187H mutation impairs ADAMTS13 activity and secretion and contributes to thrombotic thrombocytopenic purpura in mice

被引:13
作者
De Cock, E. [1 ]
Hermans, C. [2 ]
De Raeymaecker, J. [3 ]
De Ceunynck, K. [1 ]
De Maeyer, B. [1 ]
Vandeputte, N. [1 ]
Vandenbulcke, A. [1 ]
Deckmyn, H. [1 ]
Rottensteiner, H. [4 ]
De Maeyer, M. [3 ]
De Meyer, S. F. [1 ]
Vanhoorelbeke, K. [1 ]
机构
[1] KU Leuven Kulak, Lab Thrombosis Res, B-8500 Kortrijk, Belgium
[2] St Luc Univ Hosp, Div Haematol, Haemostasis & Thrombosis Unit, Brussels, Belgium
[3] Katholieke Univ Leuven, Lab Biomol Modeling, Dept Chem, Biochem Mol & Struct Biol Sect, Leuven, Belgium
[4] Baxter Innovat GmbH, Vienna, Austria
关键词
ADAMTS13; protein; human; mouse; animal model; mutation; thrombotic thrombocytopenic purpura; FACTOR-CLEAVING PROTEASE; METALLOPROTEASE DOMAIN; PROTEOLYSIS; DEFICIENCY; MODULATE;
D O I
10.1111/jth.12804
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundCongenital thrombotic thrombocytopenic purpura (TTP) is characterized by mutations in the ADAMTS13 gene, which either impair protein secretion or influence ADAMTS13 (A Disintegrin-like And Metalloprotease domain with ThromboSpondin type-1 motif, member 13) activity. Phenotypic consequences of these mutations have not yet been evaluated in animal models for TTP. ObjectivesTo identify the in vitro effect of a novel ADAMTS13 mutation and to investigate whether this mutation induces TTP in vivo. MethodsAll 29 ADAMTS13 exons with exon-intron boundaries of a patient with pregnancy-onset TTP were sequenced. Wild-type and mutant ADAMTS13 proteins were both transiently and stably expressed in human embryonic kidney cells, and their activity was evaluated in vitro using fluorescence resonance energy transfer and flow assays. Molecular dynamics simulations were performed to study Ca2+ stability. Adamts13(-/-) mice were hydrodynamically injected with wild-type and mutant expression plasmids and triggered with recombinant human von Willebrand factor. ResultsWe identified a novel heterozygous c.559G>C mutation in exon 6 of the proposita's ADAMTS13 gene. This mutation resulted in a p.Asp187His substitution (p.D187H), which was located in the high affinity Ca2+-binding site in the metalloprotease domain of ADAMTS13. The homozygous p.D187H mutation down-regulated ADAMTS13 activity in vitro. Impaired proteolytic activity was linked to unstable Ca2+ binding as visualized using a molecular dynamics simulation. In addition, the p.D187H mutation affects protein secretion in vitro. In Adamts13(-/-) mice, the homozygous p.D187H mutation reduced ADAMTS13 secretion and activity and contributed to TTP when these mice were triggered with recombinant human von Willebrand factor. ConclusionsOur data indicate that the p.D187H mutation impairs ADAMTS13 activity and secretion and is responsible for TTP onset in mice.
引用
收藏
页码:283 / 292
页数:10
相关论文
共 32 条
  • [1] Zinc and calcium ions cooperatively modulate ADAMTS13 activity
    Anderson, PJ
    Kokame, K
    Sadler, JE
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (02) : 850 - 857
  • [2] Local Elongation of Endothelial Cell-anchored von Willebrand Factor Strings Precedes ADAMTS13 Protein-mediated Proteolysis
    De Ceunynck, Karen
    Rocha, Susana
    Feys, Hendrik B.
    De Meyer, Simon F.
    Uji-i, Hiroshi
    Deckmyn, Hans
    Hofkens, Johan
    Vanhoorelbeke, Karen
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (42) : 36361 - 36367
  • [3] The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity
    de Groot, Rens
    Lane, David A.
    Crawley, James T. B.
    [J]. BLOOD, 2010, 116 (16) : 3064 - 3072
  • [4] The distal carboxyterminal domains of murine ADAMTS13 influence proteolysis of platelet-decorated VWF strings in vivo
    De Maeyer, B.
    De Meyer, S. F.
    Feys, H. B.
    Pareyn, I.
    Vandeputte, N.
    Deckmyn, H.
    Vanhoorelbeke, K.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (10) : 2305 - 2312
  • [5] Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease
    De Meyer, Simon F.
    Vandeputte, Nele
    Pareyn, Inge
    Petrus, Inge
    Lenting, Peter J.
    Chuah, Marinee K. L.
    VandenDriessche, Thierry
    Deckmyn, Hans
    Vanhoorelbeke, Karen
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (09) : 1621 - 1626
  • [6] Thrombotic thrombocytopenic purpura in humans and mice
    Desch, Karl C.
    Motto, David G.
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (09) : 1901 - 1908
  • [7] ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences
    Feys, HB
    Liu, F
    Dong, N
    Pareyn, I
    Vauterin, S
    Vandeputte, N
    Noppe, W
    Ruan, C
    Deckmyn, H
    Vanhoorelbeke, K
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (05) : 955 - 962
  • [8] Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura
    Feys, Hendrik B.
    Pareyn, Inge
    Vancraenenbroeck, Renee
    De Maeyer, Marc
    Deckmyn, Hans
    Van Geet, Chris
    Vanhoorelbeke, Karen
    [J]. BLOOD, 2009, 114 (21) : 4749 - 4752
  • [9] Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura
    Furlan, M
    Robles, R
    Solenthaler, M
    Wassmer, M
    Sandoz, P
    Lammle, B
    [J]. BLOOD, 1997, 89 (09) : 3097 - 3103
  • [10] Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura
    Furlan, M
    Robles, R
    Solenthaler, M
    Lämmle, B
    [J]. BLOOD, 1998, 91 (08) : 2839 - 2846